3 464

Cited 41 times in

A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study

DC Field Value Language
dc.contributor.author금웅섭-
dc.date.accessioned2015-04-24T17:33:37Z-
dc.date.available2015-04-24T17:33:37Z-
dc.date.issued2009-
dc.identifier.issn0360-3016-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/105631-
dc.description.abstractPURPOSE: We evaluated the efficacy of synchronous three-dimensional (3D) conformal boost to the gross tumor volume (GTV) in concurrent chemoradiotherapy for patients with locally advanced non-small-cell lung cancer (NSCLC). METHODS AND MATERIALS: Eligibility included unresectable Stage III NSCLC with no pleural effusion, no supraclavicular nodal metastases, and Eastern Cooperative Oncology Group performance score of 0-1. Forty-nine patients with pathologically proven NSCLC were enrolled. Eighteen patients had Stage IIIA and 31 had Stage IIIB. By using 3D conformal radiotherapy (RT) techniques, a dose of 1.8 Gy was delivered to the planning target volume with a synchronous boost of 0.6 Gy to the GTV, with a total dose of 60 Gy to the GTV and 45 Gy to the planning target volume in 25 fractions during 5 weeks. All patients received weekly chemotherapy consisting of paclitaxel and carboplatin during RT. RESULTS: With a median follow-up of 36.8 months (range, 29.0-45.5 months) for surviving patients, median survival was 28.1 months. One-, 2- and 3-year overall survival rates were 77%, 56.4%, and 43.8%, respectively. Corresponding local progression-free survival rates were 71.2%, 53.7%, and 53.7%. Compliance was 90% for RT and 88% for chemotherapy. Acute esophagitis of Grade 2 or higher occurred in 29 patients. Two patients with T4 lesions died of massive bleeding and hemoptysis during treatment (Grade 5). Overall late toxicity was acceptable. CONCLUSIONS: Based on the favorable outcome with acceptable toxicity, the acceleration scheme using 3D conformal GTV boost in this trial is warranted to compare with conventional fractionation in a Phase III trial.-
dc.description.statementOfResponsibilityopen-
dc.format.extent1397~1404-
dc.relation.isPartOfINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use-
dc.subject.MESHCarboplatin/administration & dosage-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/drug therapy-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/mortality-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/pathology-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/radiotherapy*-
dc.subject.MESHCombined Modality Therapy/methods-
dc.subject.MESHDose Fractionation-
dc.subject.MESHFemale-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHHumans-
dc.subject.MESHKorea-
dc.subject.MESHLung Neoplasms/drug therapy-
dc.subject.MESHLung Neoplasms/mortality-
dc.subject.MESHLung Neoplasms/pathology-
dc.subject.MESHLung Neoplasms/radiotherapy*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPaclitaxel/administration & dosage-
dc.subject.MESHRadiotherapy, Conformal/methods*-
dc.subject.MESHSurvival Analysis-
dc.subject.MESHTreatment Failure-
dc.subject.MESHTumor Burden-
dc.titleA Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Radiation Oncology (방사선종양학)-
dc.contributor.googleauthorKWAN HO CHO-
dc.contributor.googleauthorSUNG JA AHN-
dc.contributor.googleauthorHONG RYULL PYO-
dc.contributor.googleauthorKYU-SIK KIM-
dc.contributor.googleauthorYOUNGCHUL KIM-
dc.contributor.googleauthorSUNG HO MOON-
dc.contributor.googleauthorJI-YOUN HAN-
dc.contributor.googleauthorHEUNG TAE KIM-
dc.contributor.googleauthorWOONG SUB KOOM-
dc.contributor.googleauthorJIN SOO LEE-
dc.identifier.doi10.1016/j.ijrobp.2008.10.020-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00273-
dc.relation.journalcodeJ01157-
dc.identifier.eissn1879-355X-
dc.identifier.pmid19117690-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0360301608036523-
dc.contributor.alternativeNameKoom, Woong Sub-
dc.contributor.affiliatedAuthorKoom, Woong Sub-
dc.citation.volume74-
dc.citation.number5-
dc.citation.startPage1397-
dc.citation.endPage1404-
dc.identifier.bibliographicCitationINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol.74(5) : 1397-1404, 2009-
dc.identifier.rimsid40929-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.